Dominguez-Mozo M, Galan V, Ramio-Torrenta L, Quiroga A, Quintana E, Villar L
Front Immunol. 2024; 15:1384411.
PMID: 38911861
PMC: 11190074.
DOI: 10.3389/fimmu.2024.1384411.
Elsayed N, Aston P, Bayanagari V, Shukla S
Front Immunol. 2022; 13:972160.
PMID: 36045671
PMC: 9420973.
DOI: 10.3389/fimmu.2022.972160.
Yates R, Pansieri J, Li Q, Bell J, Yee S, Palace J
Brain Pathol. 2021; 32(4):e13041.
PMID: 34904300
PMC: 9245937.
DOI: 10.1111/bpa.13041.
Ehtesham N, Zare Rafie M, Mosallaei M
BMC Neurol. 2021; 21(1):246.
PMID: 34182943
PMC: 8237453.
DOI: 10.1186/s12883-021-02267-9.
Gontika M, Anagnostouli M
Mult Scler Int. 2019; 2018:8487471.
PMID: 30595920
PMC: 6282147.
DOI: 10.1155/2018/8487471.
Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset.
Tao C, Simpson Jr S, Taylor B, Blizzard L, Lucas R, Ponsonby A
Front Neurol. 2018; 9:418.
PMID: 29937751
PMC: 6003245.
DOI: 10.3389/fneur.2018.00418.
Deconstruction of HLA-DRB1*04:01:01 and HLA-DRB1*15:01:01 class II haplotypes using next-generation sequencing in European-Americans with multiple sclerosis.
Creary L, Mallempati K, Gangavarapu S, Caillier S, Oksenberg J, Fernandez-Vina M
Mult Scler. 2018; 25(6):772-782.
PMID: 29683085
PMC: 6365219.
DOI: 10.1177/1352458518770019.
Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.
George M, Briggs F, Shao X, Gianfrancesco M, Kockum I, Harbo H
Neurol Genet. 2016; 2(4):e87.
PMID: 27540591
PMC: 4974846.
DOI: 10.1212/NXG.0000000000000087.
Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis.
Isobe N, Keshavan A, Gourraud P, Zhu A, Datta E, Schlaeger R
JAMA Neurol. 2016; 73(7):795-802.
PMID: 27244296
PMC: 5081075.
DOI: 10.1001/jamaneurol.2016.0980.
Genetic determinants of risk and progression in multiple sclerosis.
Didonna A, Oksenberg J
Clin Chim Acta. 2015; 449:16-22.
PMID: 25661088
PMC: 4524789.
DOI: 10.1016/j.cca.2015.01.034.
The intelligent use and clinical benefits of electronic medical records in multiple sclerosis.
Davis M, Haines J
Expert Rev Clin Immunol. 2014; 11(2):205-11.
PMID: 25495075
PMC: 4638194.
DOI: 10.1586/1744666X.2015.991314.
Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine.
Samandary S, Kridane-Miledi H, Sandoval J, Choudhury Z, Langa-Vives F, Spencer D
Hum Immunol. 2014; 75(8):715-29.
PMID: 24798939
PMC: 4119854.
DOI: 10.1016/j.humimm.2014.04.016.
Oligoclonal bands and age at onset correlate with genetic risk score in multiple sclerosis.
Harbo H, Isobe N, Berg-Hansen P, Bos S, Caillier S, Gustavsen M
Mult Scler. 2013; 20(6):660-8.
PMID: 24099750
PMC: 4066985.
DOI: 10.1177/1352458513506503.
The importance of HLA DRB1 gene allele to clinical features and disability in patients with multiple sclerosis in Lithuania.
Balnyte R, Rastenyte D, Vaitkus A, Mickeviciene D, Skrodeniene E, Vitkauskiene A
BMC Neurol. 2013; 13:77.
PMID: 23837503
PMC: 3716946.
DOI: 10.1186/1471-2377-13-77.
HLA class I & II alleles in multiple sclerosis patients from Puerto Rico.
Miranda M, Suarez E, Abbas M, Chinea A, Tosado R, Mejias I
Bol Asoc Med P R. 2013; 105(1):18-23.
PMID: 23767380
PMC: 4573578.
Progress in multiple sclerosis genetics.
Goris A, Pauwels I, Dubois B
Curr Genomics. 2013; 13(8):646-63.
PMID: 23730204
PMC: 3492804.
DOI: 10.2174/138920212803759695.
The genetics of multiple sclerosis: an up-to-date review.
Gourraud P, Harbo H, Hauser S, Baranzini S
Immunol Rev. 2012; 248(1):87-103.
PMID: 22725956
PMC: 5967887.
DOI: 10.1111/j.1600-065X.2012.01134.x.
Replication study of multiple sclerosis (MS) susceptibility alleles and correlation of DNA-variants with disease features in a cohort of Austrian MS patients.
Schmied M, Zehetmayer S, Reindl M, Ehling R, Bajer-Kornek B, Leutmezer F
Neurogenetics. 2012; 13(2):181-7.
PMID: 22411505
DOI: 10.1007/s10048-012-0316-y.
HLA B*44: protective effects in MS susceptibility and MRI outcome measures.
Healy B, Liguori M, Tran D, Chitnis T, Glanz B, Wolfish C
Neurology. 2010; 75(7):634-40.
PMID: 20713950
PMC: 2931768.
DOI: 10.1212/WNL.0b013e3181ed9c9c.
Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients.
Jensen C, Stankovich J, van der Walt A, Bahlo M, Taylor B, van der Mei I
PLoS One. 2010; 5(4):e10003.
PMID: 20368992
PMC: 2848851.
DOI: 10.1371/journal.pone.0010003.